Medical information Clinical review pending

Gynecological Testing

Maternal Serum Screen 4 Quadruple Test

The Maternal Serum Screen 4 Quadruple Test is a prenatal screening performed between 14-22 weeks of pregnancy to assess the risk of certain genetic conditions in the fetus by measuring four key substances in the mother's blood.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Maternal blood sample (serum).
Results: Confirm with the laboratory before booking.
Preparation: Confirm with the laboratory before booking. Provide accurate information regarding gestational age (LMP or ultrasound details), maternal date of birth, IVF status, number of fetuses, diabetic status, body weight, smoking status, and any previous history of Trisomy 21 pregnancy. A completed Maternal Serum Screen requisition form (Form 11) is required.

Test priceKSh 9,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Maternal Serum Screen 4 Quadruple Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Pregnant women between 14 and 22 weeks gestation.
✓Women aged 35 years or older at delivery.
✓Women with a family history of genetic disorders.
✓Women with previous pregnancies affected by genetic abnormalities.
✓Women concerned about fetal health.
✓Women undergoing fertility treatments (e.g., IVF).

In plain language

What this test helps you understand

This screening test helps assess the risk of certain chromosomal abnormalities (like Down syndrome, Trisomy 18) and neural tube defects in the fetus during pregnancy. It aids in identifying pregnancies that may benefit from further diagnostic testing.

The Maternal Serum Screen 4 Quadruple Test is an important prenatal screening tool used to evaluate the risk of specific genetic conditions in a developing fetus. This test provides valuable information for expectant parents and healthcare providers, helping to identify potential risks early in pregnancy. It involves measuring the levels of four specific substances in the mother's blood serum. These markers help assess the likelihood of chromosomal abnormalities, such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and neural tube defects. This screening is typically recommended for pregnant women within a specific gestational age range. Understanding the results can guide further decisions regarding prenatal care and potential diagnostic testing. This test is a screening test, not a diagnostic test. Abnormal results may indicate a higher risk and warrant further investigation with diagnostic tests like amniocentesis or chorionic villus sampling (CVS).

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationConfirm with the laboratory before booking. Provide accurate information regarding gestational age (LMP or ultrasound details), maternal date of birth, IVF status, number of fetuses, diabetic status, body weight, smoking status, and any previous history of Trisomy 21 pregnancy. A completed Maternal Serum Screen requisition form (Form 11) is required.

SampleMaternal blood sample (serum).

MethodologyImmunofluorescence or chemiluminescence assay to measure the levels of Alpha-fetoprotein (AFP), Beta HCG, Free Estriol, and Inhibin A in maternal serum.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This is a screening test, not a diagnostic test. Results indicate risk, not certainty. False positives and false negatives can occur. Accuracy is dependent on accurate gestational age dating. Results can be affected by factors like multiple pregnancies, diabetes, and smoking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

This test screens for the risk of Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and neural tube defects in the fetus.

The test is typically performed between 14 and 22 weeks of gestation, with the ideal range being 15-20 weeks.

No, this is a screening test. It assesses risk but does not provide a definitive diagnosis. Further diagnostic tests may be needed if results indicate an increased risk.

You will need to provide details such as your date of birth, last menstrual period or ultrasound details, IVF status, number of fetuses, diabetic status, body weight, smoking status, and any relevant pregnancy history.

If the results suggest an increased risk, your doctor will discuss the findings with you and may recommend further diagnostic testing, such as amniocentesis or chorionic villus sampling (CVS).

You can book the test by calling or WhatsApping us at +254711564616. We have branches in major cities and offer home sample collection.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp